Last reviewed · How we verify

NCT02946268

Optimal Volume, Rate, and Interval of Bolus Nerve Catheters for Shoulder Surgery

Withdrawn Phase 4 Last updated 13 November 2019
What this trial tests

Phase 4 trial testing Ropivacaine in Pain. Withdrawn.

Timeline
21 February 2017
Primary endpoint
21 February 2017
21 February 2017

Quick facts

Lead sponsorDuke University
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposesupportive care
Start date21 February 2017
Primary completion21 February 2017
Estimated completion21 February 2017
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Duke University

Who can join

18 and older, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the ideal delivery of local anesthetics for pain control when using continuous interscalene peripheral nerve catheters for shoulder surgery. The study will be conducted in three stages. In the first stage the ideal bolus volume of ropivacaine will be determined. In the second stage the optimal rate of delivery of the bolus (infusion rate) will be determined. Finally, once both the ideal volume and infusion rate has been determined, the optimal interval between boluses of local anesthetic will be determined.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ropivacaine

Trials testing the same drug.

Other recruiting trials for Pain

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02946268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing